INGN earnings

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2026 financial results after the market closes on Thursday, May 7, 2026. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: U.S. domestic callers (877) 841-3961 Non-U.S. callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen I

Delivered full year revenue growth of approximately 4% Significantly improved profitability with 2025 net loss of $22.7 million and positive adjusted EBITDA of $2.7 million Well-positioned to accelerate expected 2026 revenue growth and profitability Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the full year ended December 31, 2025 and provided 2026 guidance for the first quarter and full year. "In 2025, we made significant progress toward our long-term profitability goals while strengthening our product portfolio and improving the fundam

Inogen to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced preliminary, unaudited revenue results for the quarter and year ended December 31, 2025. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2025 to be approximately $82 million, representing year-over-year growth of approximately 2%. Full year 2025 total preliminary, unaudited revenue is expected to be approximately $349 million, representing year-over-year growth of approximately 4%. For the full year 2025, the Com

Delivered seventh consecutive quarter of mid-single-digit revenue growth Reiterating full-year revenue guidance Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2025. Recent Highlights $92.4 million revenue, a year-over-year increase of 4.0%, marking the seventh consecutive quarter of mid-single-digit percentage growth GAAP net loss of $5.3 million and adjusted net loss of $0.5 million compared to prior year GAAP net loss of $6.0 million and adjusted net loss of $2.6 million $2.3 million adjusted EBITDA, the third consecutive quart

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025. On the same day, the Company will host a conference call at 5:30 a.m. PT / 8:30 a.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen

Delivered strong top-line results; raising full year 2025 revenue expectations Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2025. Recent Highlights Achieved second quarter 2025 revenue of $92.3 million, a year-over-year increase of 4.0%, marking the sixth consecutive quarter of mid-single-digit percentage growth. Reported GAAP net loss of $4.2 million and adjusted net loss of $0.7 million. Delivered adjusted EBITDA of $2.1 million, the second consecutive quarter of positive adjusted EBITDA. Generated $4.4 million in operating

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2025 financial results after the market closes on Thursday, August 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen I

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2025. "Inogen's strong first quarter financial results underscore our success in driving improved commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "We are making great progress and remain committed to positioning the company for sustainable growth and profitability, while creating value for all stakeholders." First Quarter 2025 Financial Results Total revenue in the first quarter of 2025 was $82.3 million, an increase of 5.5% from the prior-year p

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2025 financial results after the market closes on Wednesday, May 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investo

Results Reflect Strong Fourth Quarter 2024 Revenue Growth of 5.5%; Full-Year Revenue Growth of 6.4% Company Provides 2025 Growth Outlook Recently Announced Strategic Collaboration with Yuwell to Expand Product Portfolio, Global Reach Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter and the full year ended December 31, 2024. "2024 was a stellar year for Inogen. With our new leadership team in place, we returned the Company to growth, achieved significant milestones, and made meaningful steps towards profitability," said Kevin Smith, President and Ch

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced unaudited preliminary revenue results for the fourth quarter and the full year ended December 31, 2024. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2024 to be in the range of $79.0 million to $80.0 million, reflecting year-over-year growth of 4% to 5%. The Company estimates preliminary, unaudited total revenue for the full year 2024 to be in the range of $334.5 million to $335.5 million, reflecting year-over-year growth of 6% exceeding Inogen's previously announced full year 2024 guidance range of $329

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2024. "We continued to make significant progress on our strategic priorities in the third quarter. Our results demonstrate our team's strong commercial and operational execution," said Kevin Smith, President and Chief Executive Officer. "As we move into the fourth quarter, we remain focused on driving growth, continuing innovation, and advancing towards sustainable profitability." Third Quarter 2024 Financial Results Total revenue in the third quarter of 2024 increased 5.8% to $88.8 millio

Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Inve

Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2024. "I am proud of the performance of our team in the first half of 2024. We have made meaningful progress on our strategic initiatives, driving top-line growth and advancing the profile of the business toward profitability," said Kevin Smith, President and Chief Executive Officer. "We will also continue to advance our innovation pipeline and look forward to delivering best-in-class products to more respiratory patients around the world." Second Quarter 2024 Financial Results Second quarter

Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2024 financial results after the market closes on Tuesday, August 6, 2024. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Inv

Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2024. "We are pleased to be off to a solid start at Inogen in 2024. Looking forward, we remain focused on positioning the business for revenue growth, improving our operating discipline to drive long-term profitability, and investing in our innovation pipeline to broaden our product portfolio," said Kevin Smith, President and Chief Executive Officer. "The performance in the quarter reflects the quality of the team we have in place, and we will continue executing against our strategic priorities,

Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2024 financial results after the market closes on Tuesday, May 7, 2024. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investo

Fourth quarter 2023 revenue of $75.9 million; full-year 2023 revenue of $315.7 million Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the full-year ended December 31, 2023. "I am excited for the future of Inogen. As we progress into 2024, we are focused on positioning the business for revenue growth and long-term profitability while advancing our innovation pipeline and working to bring Physio-Assist to the U.S. market," said Kevin Smith, President and Chief Executive Officer. "We have a strong management team with the recent additions of Grégo

Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report fourth quarter and full year 2023 financial results after the market closes on Tuesday, February 27, 2024. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen's website at: http://investor.inogen.com/. This webcast wil

Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2023. Third Quarter 2023 and Recent Business Highlights Reported total revenue of $84.0 million, reflecting a decrease of 20.3% from the third quarter of 2022. Completed acquisition of Physio-Assist SAS, expanding Inogen's global respiratory care presence by addressing a sizeable, growing, and underserved airway clearance market opportunity. "We have continued to improve on executing our commercial strategy while addressing headwinds that we have faced this year. We are excited to

Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2023 financial results after the market closes on Tuesday, November 7, 2023. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen's website at: http://investor.inogen.com/. This webcast will also be archiv

Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 and Recent Business Highlights All comparisons are to the prior year period unless otherwise noted. Reported total revenue of $83.6 million, reflecting a decrease of 19.1%; currency fluctuations accounted for 0.6% of the decrease. GAAP net loss of $9.8 million, Adjusted net loss of $5.8 million and Adjusted EBITDA loss of $3.2 million. Entered into a share purchase agreement to acquire Physio-Assist to add a sizable, growing, and underserved airway clearance m

Acquisition Enables Evolution to a Global Respiratory Care Company by Adding a Sizable, Growing and Underserved Airway Clearance Market Opportunity Inogen Provides Preliminary, Unaudited Second Quarter Financial Update Inogen to Announce Second Quarter Financial Results on August 7, 2023 Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the company has entered into a definitive agreement to purchase Physio-Assist SAS, a privately-held company headquartered in France. Physio-Assist developed and manufactures Simeox, a technology-enabled airway clearance device with a proven efficacy

Total Revenue of $72.2 Million In Line with Company Expectations Rental Revenue Year-over-Year Growth of 25% Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended March 31, 2023. First Quarter 2023 Highlights All comparisons are to the prior year period unless otherwise noted. Reported total revenue of $72.2 million, in line with company expectations, reflecting a decrease of 10.2%; currency fluctuations accounted for 1.7% of the decrease. Continued progress on rental strategy led to a 25.4% increase in rental revenue, primarily due to higher ren

Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report first quarter 2023 financial results after the market closes on Thursday, May 4, 2023. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (888) 645-4404 Non-US callers (862) 298-0702 Please reference Inogen to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen's website at: http://investor.inogen.com/. This webcast will also be archived o

Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will host a conference call on Monday, February 27, 2023, at 10:00 a.m. Eastern Time. At the event, Nabil Shabshab, President and Chief Executive Officer, and Kristin Caltrider, Chief Financial Officer, will provide an update on the Company's commercial and innovation strategies. A live audio webcast and archived recording of the presentation will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. Inogen has used, and intends to continue to use, its Investor Relations website,

Fourth Quarter Year-over-Year Revenue Growth of 15.3% Full Year 2022 Year-over-Year Revenue Growth of 5.4% Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the fourth quarter and the full year ended December 31, 2022. Fourth Quarter 2022 Highlights All comparisons are to the prior year period unless otherwise noted. Reported total revenue increased 15.3% to $88.1 million, on a constant currency basis total revenue for the quarter increased 17.7%. GAAP net loss of $56.6 million, adjusted net loss of $13.0 million, and adjusted EBITDA was a loss of $10.6 million. GA

Inogen to Present at J.P. Morgan Healthcare Conference This Week Inogen to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023 Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced unaudited preliminary revenue results for the fourth quarter and the full year ended December 31, 2022. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2022 to be in the range of $87.5 million to $88.5 million, representing year-over-year growth of 14.5% to 15.8%. Full year 2022 total preliminary, unaudited revenue is expected to be in the range of $376.

Double Digit Year-over-Year Revenue Growth of 13.2% Constant Currency Year-over-Year Revenue Growth of 14.5% Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended September 30, 2022, and provided a business update. Third Quarter 2022 Highlights Reported total revenue was $105.4 million for the period ended September 30, 2022, representing a 13.2% increase from $93.1 million for the period ended September 30, 2021. On a constant currency basis, total revenue for the period ended September 30, 2022, increased 14.5%. GAAP net loss of $9.5 million, adjust

Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will issue third quarter 2022 financial results before the market opens on Wednesday, November 2, 2022. On the same day, the Company will host a conference call beginning at 5:30 am PT / 8:30 am ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen's website at: http://investor.inogen.com/. This webcast will also be archived

Robust Sequential Revenue Growth Driven by Fulfilled Demand Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2022 and provided a business update. Second Quarter 2022 Highlights Reported total revenue was $103.4 million for the period ended June 30, 2022, representing a 1.8% increase from $101.6 million for the period ended June 30, 2021. On a constant currency basis, total revenue for the period ended June 30, 2022, increased 3.6% from $101.6 million for the period ended June 30, 2021. Total revenue also represented a 28.6% increase from

Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release second quarter 2022 financial results after market close on Thursday, August 4, 2022. The Company will host a corresponding conference call beginning at 2:00 pm PT/5:00 pm ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 International callers (201) 689-8589 Please reference Inogen to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen's website at: http://investor.inogen.com/. A replay of the call will be availab

Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release first quarter 2022 financial results after market close on Thursday, May 5, 2022. The Company will host a corresponding conference call beginning at 2:00pm PT/5:00pm ET. Individuals interested in listening to the conference call may do so by dialing (877) 841-3961 for domestic callers or (201) 689-8589 for international callers. Please reference Inogen to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen's website at: http://investor.inogen.com/. A replay of the call will be availab

– Q4 2021 Total Revenue increased 3.3% year-over-year to $76.4 million – Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three- and twelve-month periods ended December 31, 2021. Fourth Quarter 2021 Highlights Total revenue of $76.4 million, up 3.3% from the same period in 2020, in line with the mid-point of its preliminary, unaudited revenue estimate provided on January 10, 2022 Domestic direct-to-consumer revenue of $33.0 million, up 23.3% from the same period in 2020 Rental revenue of $13.0 million, up 39.4% from the same period in 2020 Full Year 2021 Highl

Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release fourth quarter 2021 financial results after market close on Thursday, February 24, 2022. The Company will host a corresponding conference call beginning at 2:00pm PT/5:00pm ET. Individuals interested in listening to the conference call may do so by dialing (877) 841-3961 for domestic callers or (201) 689-8589 for international callers. Please reference Inogen to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen's website at: http://investor.inogen.com/. A replay of the call will be

– Q3 2021 Total Revenue increased 25.3% from the same period in 2020 to $93.1 million – Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three months ended September 30, 2021. Third Quarter 2021 Highlights Total revenue of $93.1 million, up 25.3% from the same period in 2020 Domestic direct-to-consumer revenue of $36.3 million, up 24.6% from the same period in 2020 Rental revenue of $12.1 million, up 61.3% from the same period in 2020 Signed agreement with Ashfield Healthcare, LLC (contract sales organization) to enhance the Company's go-to-market capabilities

Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will release third quarter 2021 financial results after market close on Thursday, November 4, 2021. The Company will host a corresponding conference call beginning at 2:00pm PT/5:00pm ET. Individuals interested in listening to the conference call may do so by dialing (877) 841-3961 for domestic callers or (201) 689-8589 for international callers. Please reference Inogen to join the call. To listen to a live webcast, please visit the Investor Relations section of Inogen's website at: http://investor.inogen.com/. A replay of the call will be av

– Q2 2021 Record Total Revenue of $101.6 million, up 41.7% from the same period in 2020 – Inogen, Inc. (NASDAQ:INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial results for the three months ended June 30, 2021. Second Quarter 2021 Highlights Total revenue of $101.6 million, up 41.7% from the same period in 2020, primarily due to strong consumer demand, improved average selling prices in all channels, and reduced COVID-19 pandemic-related impacts Domestic direct-to-consumer revenue of $40.9 million, up 35.6% from the same period in 2020 Rental revenue of $11.3 million, up 85.2% from the same period